acipimox (250 mg), a long-acting antilipolytic drug, or placebo was given overnight (at 7:00 p.m., 1:00 a.m., 7:00 a.m.) to 9 lean control subjects, 13 obese nondiabetic subjects, 10 obese subjects with impaired glucose tolerance, and 11 patients with type 2 diabetes.